BDSI is a biotechnology company that researches and commercializes proprietary drugs for the treatment of pain management and addiction.Read more
Collegium Pharmaceutical is seen as one of BDSI's biggest rivals. Collegium Pharmaceutical is headquartered in Stoughton, Massachusetts, and was founded in 2003. Like BDSI, Collegium Pharmaceutical also works within the Pharmaceuticals sector. Collegium Pharmaceutical generates 198% the revenue of BDSI.
Zyla Life Sciences is seen as one of BDSI's top competitors. Zyla Life Sciences was founded in 1995, and its headquarters is in Wayne, Pennsylvania. Zyla Life Sciences operates in the Pharmaceuticals industry. Zyla Life Sciences has 37 fewer employees than BDSI.
September 22, 2021
BDSI's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 450.7M. Over the last four quarters, BDSI's revenue has grown by 5.1%. Specifically, in Q2 2021's revenue was $41.4M; in Q1 2021, it was $41M; in Q4 2020, it was $42.2M; in Q3 2020, BDSI's revenue was $39.4M.
These are all the companies that BDSI has acquired. BDSI's latest acquisition was Arius Pharmaceuticals in Aug 2004.
Since BDSI was founded in 1997, it has participated in 8 rounds of funding. In total BDSI has raised $206.2M. BDSI's last funding round was on May 2018 for a total of $50.0M
No recent investments found related to BDSI